medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2015, Number 4

<< Back Next >>

Ann Hepatol 2015; 14 (4)

Hypovitaminosis D and its relation to demographic and laboratory data among hepatitis C patients

Melo-Villar L, Lampe E, de Almeida AJ, Scalioni LP, Lewis-Ximenez LL, Miguel JC, Del Campo JA, Ranchal I, Villela-Nogueira CA, Romero-Gomez M

Language: English
References: 27
Page: 457-463
PDF size: 123.61 Kb.


ABSTRACT

Background. The relationship between 25-hydroxyvitamin D [25(OH)D] serum levels and response to antiviral therapy and laboratory data in HCV infection remains unclear. The aim of this study was to determine pre-treatment 25(OH)D serum level among HCV infected individuals and to evaluate the association between vitamin D status, virological response, and laboratory data. Material and methods. Baseline serum 25(OH)D levels were measured in 237 chronic HCV infected patients (139 female, age 53.7 ± 11.2 years) using chemiluminescence immunoassay. Correlations between serum 25(OH)D levels, virological and laboratory data regarding HCV infection as well as sustained virological response (SVR) to antiviral therapy were evaluated. Results. Mean serum values of 25(OH)D was 26.2 ± 12 ng/mL and prevalence of vitamin D deficiency (‹ 30 ng/mL) was 66.2%. Advanced age (› 55 years), high mean values of LDL, total cholesterol, HDL and low mean values of alkaline phosphatase and hemoglobin were statistically associated to vitamin D deficiency. Antiviral treatment was underwent by 133 HCV patients and 44.3% of them achieved SVR. Most of individuals that presented SVR also presented 25(OH)D level higher than 30ng/mL (55.9%). SVR was associated to low mean values of LDL, total cholesterol and platelets; high mean values of ALT, AST and low fibrosis grade. Conclusions: In conclusion, low vitamin D levels were observed among HCV infected patients and was associated to laboratory findings, however baseline 25(OH)D level is not independently associated with SVR.


REFERENCES

  1. Petta S, Cammà C, Scazzone C, Tripodo C, Di Marco V, Bono A, Cabibi D, et al. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon- based therapy in genotype 1 chronic hepatitis C. 15. Hepatology 2010; 51: 1158-67.

  2. Steinvil A, Leshem-Rubinow E, Berliner S, Justo D, Finn T, Ish-shalom M, Birati EI, et al. Vitamin D deficiency prevalence and cardiovascular risk in Israel. Eur J Clin Invest 2011; 41: 263-8.

  3. Fleet JC, DeSmet M, Johnson R, Li Y. Vitamin D and cancer: a review of molecular mechanisms. Biochem J 2012; 441: 61-76.

  4. O’Brien MA, Jackson MW. Vitamin D and the immune system: Beyond rickets. Vet J 2012; 194: 27-33.

  5. Sung CC, Liao MT, Lu KC, Wu CC. Role of vitamin D in insulin resistance. J Biomed Biotechnol 2012; 2012: 634195.

  6. Stokes CS, Krawczyk M, Reichel C, Lammert F, Grünhage F. Vitamin D deficiency is associated with mortality in patients with advanced liver cirrhosis. Eur J Clin Invest 2014; 44(2): 176-83.

  7. Petta S, Grimaudo S, Marco VD, Scazzone C, Macaluso FS, Cammà C, Cabibi D, et al. Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients. J Viral Hepat 2013; 20: 486-93.

  8. Baur K, Mertens JC, Schmitt J, Iwata R, Stieger B, Eloranta JJ, Frei P, et al. Combined effect of 25-OH vitamin D plasma levels and genetic Vitamin D Receptor (NR 1I1) vari ants on fibrosis progression rate in HCV patients. Liver Int 2012; 32: 635-43.

  9. Terrier B, Jehan F, Munteanu M, Geri G, Saadoun D, Sène D, Poynard T, et al. Low 25-hydroxyvitamin D serum levels correlate with the presence of extra-hepatic manifestations in chronic hepatitis C virus infection. Rheumatology (Oxford) 2012; 51: 2083-90.

  10. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17: 107-15.

  11. Klenerman P, Gupta PK. Hepatitis C virus: current concepts and future challenges. QJM 2012; 105: 29-32.

  12. Eslam M, Aparcero R, Kawaguchi T, Del Campo JA, Sata M, Khattab MA, Romero-Gomez M. Meta-analysis: insulin resistance and sustained virological response in hepatitis C. Aliment Pharmacol Ther 2011; 34: 297-305.

  13. de Rueda PM, López-Nevot MÁ, Sáenz-López P, Casado J, Martín-Casares A, Palomares P, Quiles R, et al. Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin. Am J Gastroenterol 2011; 106: 1246-54.

  14. Bitetto D, Fattovich G, Fabris C, Ceriani E, Falleti E, Fornasieri E, Pasino M, et al. Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. Hepatology 2011; 53: 1118-26.

  15. Nimer A, Mouch A. Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients. World J Gastroenterol 2012; 18: 800-5.

  16. Abu-Mouch S, Fireman Z, Jarchovsky J, Zeina AR, Assy N. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World J Gastroenterol 2011; 17: 5184-90.

  17. Eslam M, Kawaguchi T, Del Campo JA, Sata M, Khattab MA, Romero-Gomez M. Use of HOMA-IR in hepatitis C. J Viral Hepat 2011; 18: 675-84.

  18. Idrees M. Development of an improved genotyping assay for the detection of hepatitis C virus genotypes and subtypes in Pakistan. J Virol Methods 2008; 150: 50-6.

  19. Martínez SM, Crespo G, Navasa M, Forns X. Noninvasive assessment of liver fibrosis. Hepatology 2011; 53: 325-35.

  20. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-87.

  21. Ladero JM, Torrejón MJ, Sánchez-Pobre P, Suárez A, Cuenca F, de la Orden V, Devesa MJ, et al. Vitamin D deficiency and vitamin D therapy in chronic hepatitis C. Ann Hepatol 2013; 12: 199-204.

  22. Villar LM, Del Campo JA, Ranchal I, Lampe E, Romero- Gomez M. Association between vitamin D and hepatitis C virus infection: A meta-analysis. World J Gastroenterol 2013; 19: 5917-24.

  23. Kitson MT, Dore GJ, George J, Button P, McCaughan GW, Crawford DH, Sievert W, et al. Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. J Hepatol 2013; 58: 467-72.

  24. Guzmán-Fulgencio M, García-Álvarez M, Berenguer J, Jiménez-Sousa MA, Cosín J, Pineda-Tenor D, Carrero A, et al. Vitamin D deficiency is associated with severity of liver disease in HIV/HCV coinfected patients. J Infect 2014; 68: 176-84.

  25. Berg T, Andreone P, Pol S, Roberts S, Younossi Z, Diago M, Lawitz EJ, et al. Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment- experienced HCV genotype 1 patients: REALIZE study. Liver Int 2014.

  26. Niederau C, Mauss S, Schober A, Stoehr A, Zimmermann T, Waizmann M, Moog G, et al. Predictive factors for sustained virological response after treatment with pegylated interferon α-2a and ribavirin in patients infected with HCV genotypes 2 and 3. PLoS One 2014; 9: e107592.

  27. Ferreira PR, da Silva MH, Brandão-Melo CE, Rezende RE, Gonzalez M, Reuter T, Urbaez JD, et al. The clinical effectiveness of pegylated interferon and ribavirin for the treatment of chronic hepatitis C in HIV-infected patients in Brazil: a multicentric study. Braz J Infect Dis 2014.




2020     |     www.medigraphic.com